Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 9/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17613400 | 0.87 | TRPV1 (0.39) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL15268007 | 0.83 | SLC40A1 (0.35) | HTR1AADRA1DADRA1AADRA1BKDM4E | |
| SCHEMBL13230497 | 0.81 | LATS1 (0.33) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL15290719 | 0.81 | IDO1 (0.40) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL17613404 | 0.80 | IDO1 (0.39) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL15268009 | 0.76 | HTR1A (0.38) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL13262272 | 0.76 | KDM4E (0.40) | GRM1KDM4ELMNAHTT | |
| SCHEMBL15268011 | 0.76 | HTT (0.41) | HTR1AADRA1DADRA1AADRA1BIDO1 | |
| SCHEMBL17613403 | 0.71 | CXCR4 (0.43) | IDO1 | |
| SCHEMBL13230456 | 0.71 | LATS1 (0.34) | HTR1AADRA1DADRA1AADRA1BIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249138-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213595-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | HTR1A 4719/4885ADRA1D 4642/4885ADRA1A 4479/4885 |
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HTR1A 4719/4885ADRA1D 4642/4885ADRA1A 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.